Abstract
In comparison to earlier treatment standards (including chemotherapy, radiation therapy, and surgery), immunotherapy has significantly improved patients' survival and quality of life. Immunotherapy is ultimately a broad term that encompasses a variety of therapeutics. Immunotherapeutic approaches have firmly established themselves as a new pillar of cancer care, ranging from neoadjuvant and adjuvant strategies to the metastatic phase in various entities. In this review article, we highlight which immunotherapies are currently standard in oncological care, with a strong focus on immune checkpoint inhibitors (ICIs), their limitations, and the commonly occurring side effects.
| Translated title of the contribution | Which Immunotherapies are Standard Today? And What Side Effects Should be Expected? |
|---|---|
| Original language | German |
| Journal | Zentralblatt fur Chirurgie - Zeitschrift fur Allgemeine, Viszeral- und Gefasschirurgie |
| Volume | 150 |
| Issue number | 2 |
| Pages (from-to) | 170-174 |
| Number of pages | 5 |
| ISSN | 0044-409X |
| DOIs | |
| Publication status | Published - 08.04.2025 |
Research Areas and Centers
- Research Area: Luebeck Integrated Oncology Network (LION)
- Academic Focus: Center for Infection and Inflammation Research (ZIEL)
DFG Research Classification Scheme
- 2.22-14 Hematology, Oncology
- 2.21-05 Immunology
